UPDATE: Cleveland BioLabs Provides Update on Barda Development Proposal

Cleveland BioLabs (Nasdaq: CBLI ) today announced that the Biomedical Advanced Research and Development Authority ("BARDA") has terminated negotiations related to the Company's proposal for further development of Entolimod as a medical radiation countermeasure, noting that all such negotiations are subject to the availability of funds.